(Q38010802)

26 August 2017

title

Antiangiogenic therapies in glioblastoma multiforme (English)

1 reference

26 August 2017

main subject

angiogenesis inhibitor

1 reference

1 reference

Mairéad G McNamara

1

1 reference

26 August 2017

Warren P Mason

series ordinal

2

1 reference

26 August 2017

publication date

1 May 2012

1 reference

Expert Review of Anticancer Therapy

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

643-654

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

26 August 2017

cites work

1 reference

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

21 January 2018

1 reference

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

Angiogenesis in brain tumours

21 January 2018

1 reference

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

21 January 2018

1 reference

Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study

21 January 2018

1 reference

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

Bevacizumab: in previously treated glioblastoma

21 January 2018

1 reference

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

21 January 2018

1 reference

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.

21 January 2018

1 reference

Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas

21 January 2018

1 reference

VEGF Trap induces antiglioma effect at different stages of disease

21 January 2018

1 reference

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study

21 January 2018

1 reference

VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma.

21 January 2018

1 reference

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

21 January 2018

1 reference

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma

21 January 2018

1 reference

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

21 January 2018

1 reference

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

21 January 2018

1 reference

Sorafenib exerts anti-glioma activity in vitro and in vivo

21 January 2018

1 reference

Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3

21 January 2018

1 reference

Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme

21 January 2018

1 reference

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

21 January 2018

1 reference

Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model

21 January 2018

1 reference

Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy

21 January 2018

1 reference

Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma

21 January 2018

1 reference

Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure.

21 January 2018

1 reference

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

21 January 2018

1 reference

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide

21 January 2018

1 reference

EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma

21 January 2018

1 reference

Integrins: molecular targets in cancer therapy

21 January 2018

1 reference

Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro

21 January 2018

1 reference

Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency

21 January 2018

1 reference

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme

21 January 2018

1 reference

A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme

21 January 2018

1 reference

A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma

21 January 2018

1 reference

A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.

21 January 2018

1 reference

AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts

21 January 2018

1 reference

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

21 January 2018

1 reference

Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2

21 January 2018

1 reference

The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.

21 January 2018

1 reference

In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation

21 January 2018

1 reference

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

21 January 2018

1 reference

Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome

21 January 2018

1 reference

Adverse effects of anticancer agents that target the VEGF pathway

21 January 2018

1 reference

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

21 January 2018

1 reference

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria

21 January 2018

1 reference

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

21 January 2018

1 reference

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

21 January 2018

1 reference

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

21 January 2018

1 reference

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape

21 January 2018

1 reference

Differential diagnosis of pancreatic tumors using ultrasound contrast imaging.

21 January 2018

1 reference

Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?

21 January 2018

1 reference

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501

21 January 2018

1 reference

Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme

21 January 2018

1 reference

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

21 January 2018

1 reference

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer

21 January 2018

1 reference

Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.

21 January 2018

1 reference

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

21 January 2018

1 reference

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.12.35

1 reference

26 August 2017

1 reference